1

# Validation of a HIV Whole Genome Sequencing Method for HIV Drug Resistance Testing in an Australian Clinical Microbiology Laboratory

Frances JENKINS<sup>1</sup>, Thomas LE<sup>1</sup>, Rima FARHAT<sup>1</sup>, Angie PINTO<sup>1,2</sup>, M Azim ANZARI<sup>3</sup>, David BONSALL<sup>3</sup>, Tanya GOLUBCHIK<sup>4</sup>, Rory BOWDEN<sup>5</sup>, Frederick J LEE<sup>,6,7</sup>, Sebastiaan VAN HAL<sup>1,7</sup>

# <sup>1</sup>Department of Infectious Diseases and Microbiology, Royal Prince Alfred Hospital, Sydney, Australia

<sup>2</sup> The Kirby Institute, UNSW Australia, Sydney, Australia

<sup>3</sup> Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom

<sup>4</sup> Department of Medical Sciences, Faculty of Medicine and Health, University of Sydney,

### Sydney, Australia

<sup>5</sup> The Walter and Eliza Hall Institute of Medical Research, Advanced Genomics Facility, Melbourne, Australia

<sup>6</sup> Department of Clinical Immunology and Allergy, Royal Prince Alfred Hospital, Sydney, Australia7 Sydney Medical School, University of Sydney, Sydney, Australia

**Corresponding author:** Sebastiaan van Hal, Department of Infectious Diseases and Microbiology, Royal Prince Alfred Hospital, Missenden Road, Camperdown NSW 2050, Sydney, Australia (sebastiaan.vanhal@health.nsw.gov.au)

2

**Abstract:** Detection of HIV drug resistance is vital to successful anti-retroviral therapy (ART). HIV drug resistance (HIVDR) testing to determine drug resistance mutations (DRMs) is routinely performed in Australia to guide ART choice in either newly diagnosed people living with HIV or in cases of treatment failure. In 2022, our Australian clinical microbiology laboratory sought to validate a Next-generation sequencing (NGS)-based HIVDR assay to replace the previous Sanger sequencing (SS)-based ViroSeq assay. NGS solutions for HIVDR offer higher throughput, lower costs and higher sensitivity for variant detection. We sought to validate the previously described low-cost probe-based NGS method (veSEQ-HIV) for HIV-1 recovery and HIVDR testing in a diagnostic setting. The implemented veSEQ-HIV assay displayed 100% and 98% accuracy in major and minor mutation detection respectively and 100% accuracy of subtyping (provided >1000 mapped reads were obtained). Pairwise comparison exhibited low inter-and intra-run variability across the whole genome (Jaccard similarity coefficient [J] =0.993; J=0.972) and limited to the Pol gene only (J=0.999; J=0.999) respectively. The veSEQ-HIV assay met all our pre-set criteria based on the WHO "Recommended methods for validating an in-house genotyping assay for surveillance of HIV drug resistance" and has successfully replaced the ViroSeq assay in our laboratory.Scalingdown the veSEQ-HIV assay to a limited batch size and sequencing on the Illumina iSeq100, allowed easy implementation of the assay into the workflow of a small sequencing laboratory with minimal staff and equipment and the ability to meet clinically relevant test turn-around times.

**Keywords:** HIV, HIVDR, NGS, whole genome sequencing, drug resistance, genotyping, viral genomics, Illumina, antiretroviral therapy

#### 3

### 1 Introduction

2	HIV is a major public health concern worldwide. While Australia has a low prevalence of
3	HIV in the general population (0.1% on 2017 estimate), HIV detection and management still
4	play an important role in transmission prevention especially in at-risk populations (Guy,
5	2007; Kirby Institute, 2018). HIV drug resistance (HIVDR) testing to determine drug
6	resistance mutations (DRMs) is routinely performed in Australia to improve chances of
7	treatment success by informing anti-retroviral therapy (ART) choice in newly-diagnosed
8	people living with HIV or in cases of treatment failure.
9	Royal Prince Alfred Hospital in Sydney, Australia routinely performs HIVDR testing and
10	from 2016 until 2021, utilised the Sanger sequencing (SS) based commercial assay, ViroSeq
11	HIV-1 genotyping system (Celera Diagnostic, Abbott Laboratories, Alameda, CA, USA).
12	The ViroSeq system includes sample purification and reverse -transcription polymerase chain
13	reaction steps, to generate a 1.8 kb amplicon covering parts of the polymerase (Pol) region
14	including the protease (PR) and partial reverse transcriptase (RT) genes. The generated
15	amplicons act as the SS template to generate an approximate 1.2kb chromatogram which after
16	manual curation acts as the sequence input to the HIVdb Program available on the Stanford
17	University HIVDR database website (https://hivdb.stanford.edu/hivdb/by-patterns/). The
18	HIVdb Program identifies known DRMs and inferred levels of drug resistance to commonly
19	used anti-retroviral drugs (Liu TF, 2006; Rhee, 2003; Shafer, 2006).
20	In 2020, our laboratory was advised that the ViroSeq system would cease manufacture in
21	mid-2021. We therefore sought to replace this assay with a suitable alternative that would be
22	able to detect DRMs in samples with a plasma viral load around 2000 copies per mL (cp/mL)
23	at similar costs and overcome several limitations of the ViroSeq system: (1) able to obtain
24	results across all HIV-1 subtypes; (2) include the integrase (IN) region; 3) able to detect sub-

4

consensus variants as several studies have demonstrated that these subpopulations contribute 25 to negative clinical outcomes (Metzner, 2009; Simen, 2009); and 4) was future-proof as novel 26 ART agents become available. Next-generation sequencing (NGS) solutions for HIVDR have 27 been proposed as superior to SS methods due to higher throughput, lower costs and improved 28 sensitivity to detection minority variants at lower levels (Lee, 2020; Taylor, 2019). Several 29 NGS-based HIVDR methods have been reported, however, the challenge remains finding 30 31 protocols that work consistently without sampling bias across all HIV-1 subtypes and viral 32 loads.

33 A robust low-cost probe-based high-throughput NGS method for HIVDR and viral load

34 (veSEQ-HIV) was previously described by Bonsall et. al (2020) (Bonsall, 2020). Previous

evaluation of its performance in comparison to ViroSeq, showed a high degree of

36 concordance in DRMs detected, comparatively higher sensitivity in detection of sub-

37 consensus variants and the ability to detect complete sequences in a majority of samples

38 (70%), increasing with viral load (Fogel, 2020).

As such, the veSEQ-HIV assay best met our requirements. However, the veSEQ-HIV assay
was designed to run in excess of 96 samples per batch (Bonsall, 2020). In our diagnostic
setting, with a need to meet clinically relevant turn-around times, we reduced this batch size
to 8 patient samples and performed sequencing on the Illumina iSeq100. These adjustments
allowed us to implement the assay into the workflow of our small sequencing laboratory with
minimal staff and equipment.

45 Here, we describe the validation of the veSEQ-HIV method in its utility for HIVDR testing as46 an in-house IVD in an Australian clinical microbiology laboratory.

5

#### 47 Materials and methods

### 48 Ethics

- 49 Human Research Ethics Committee of the Sydney Local Health District approved the use of
- stored plasma samples in this study (2019/ETH01706).

### 51 Study population/Sample selection

- 52 Sixty-six stored plasma samples with known DRMs from both treatment naïve and -
- 53 experienced people living with HIV-1 that had undergone testing on the ViroSeq system
- 54 between 2016-2021 were included. Associated plasma viral loads were obtained from
- laboratory records and ranged from 950 to  $>10^6$  cp/mL. Subtypes included B (n=48), C (n=3),
- 56 CRF01\_AE (n=13) and CRF02\_AG (n=2). Isolate baseline characteristics are summarized in
- 57 **Table 1**.
- 58 As the ViroSeq assay does not cover the IN region, we included five samples that had had
- 59 SS-based IN testing performed at an external accredited laboratory and had Stanford HIVdb
- 60 reports available. We did not have access to nucleotide sequence for these samples and only
- 61 included them in our comparisons of subtype and mutation detection.
- For reference, a dilution series  $(10^5 25 \text{ cp/mL})$  of the highest AcroMetrix HIV-1 Panel
- 63 standard was prepared (Thermo Fisher Scientific, Waltham, Massachusetts, USA).
- 64 A negative control (PCR confirmed HIV-negative plasma) was taken though the entire
- 65 process from extraction to sequencing for each run.

### 66 Nucleic acid extraction

- 67 Methods were based on those described for veSEQ-HIV (Bonsall, 2020) with minor
- 68 modifications. Briefly, automated total nucleic acid (NA) extraction was performed using the
- 69 NucliSENS e-MAG (Biomerieux, Marcy-l'Étoile, France). Extraction was performed using

6

the manufacturers general extraction protocol with an input volume of 500  $\mu$ L and elution of

71 25 μL.

### 72 cDNA generation and library preparation

- 73 NA was concentrated using RNAClean XP beads (Beckman Coulter, Brea, California, USA)
- 74 before quarter reactions for cDNA generation without RNA fragmentation were prepared
- vising the SMARTer Stranded Total RNA-Seq Kit v2 Pico Input Mammalian Kit (Takara
- 76 Biosciences USA, San Jose, California, USA) with maximal NA input.
- 77 Libraries were prepared using the same kit. Indexed libraries were pooled equally by volume
- 78 (8 patient and 1 negative control) before performing clean-up using a ratio of 0.68 Ampure
- 79 XP beads (Beckman Coulter, Brea, California, USA). DNA quantification was performed
- 80 using Qubit HS DNA kit and Qubit fluorometer (Thermo Fisher Scientific, Waltham,
- 81 Massachusetts, USA) and fragment size determined using the HS D1000 assay on Tape
- 82 Station 4200 (Agilent Technologies, Santa Clara, California, USA).

### 83 Capture-based hybridization, post-capture PCR and clean-up

- 84 Up to 500 ng of pooled library was taken through viral capture using the xGen hybridization
- and wash kit (Integrated DNA Technologies, Singapore). The probe pool contained 646
- custom 120-mer biotinylated probes targeting the HIV genome across multiple subtypes. The
- 87 custom probe sequences are published here for the first time with permission

88 (Supplementary file 2). Post-capture PCR was performed as per manufacturer's instructions.

- 89 Clean-up was performed with a ratio of 1.5x Ampure XP beads (Beckman Coulter, Brea,
- 90 California, USA). DNA quantification was performed using Qubit HS DNA kit and
- 91 fluorometer (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and fragment size
- 92 determined using HS D1000 assay on Tape Station 4200 (Agilent Technologies, Santa Clara,
- 93 California, USA). An additional post-capture PCR (6-cycles; total 16 cycles) was added and

7

94 clean-up repeated if minimum library molarity (1nM for iSeq100) was not meet at the final95 library stage.

#### 96 Sequencing

97 Final libraries were prepared for sequencing as per the Illumina iSeq 100 Sequencing System

98 Product Documentation (# 200015511 v00). A final loading concentration of 75 pM was used

99 with a 2% PhiX control spike. Libraries were run on the Illumina iSeq100 system using iSeq

100 100 il Reagent v2 (300-cycles) with read lengths of 2 x 150 bp.

### 101 **Bioinformatics**

Raw short-read data was processed by an in-house automated pipeline utilising open-source
software as described previously with minor modifications (Bonsall, 2020). Briefly, Kraken
was first used to filter out human reads followed by trimming of adapters using fastp. Hostdepleted, filtered reads were then taken forward including generating assemblies using and
SPAdes which formed the inputs to assemble the contigs suitable as input for SHIVER (v3)
(Wood DE, 2019; Wymant, 2018).

108 An updated Python 3 compliant SHIVER was used for analysis setting a previously validated

109 minimum depth of 5-15 against the reference genome (Human immunodeficiency virus type

110 1 - HBX2) (Ji, 2018). The resulting output is then run the Stanford University HIV Drug

111 Resistance database to identify drug resistance mutations using the tool sierrapy (Liu TF,

112 2006; Shafer, 2006; Rhee, 2003). Subsequent reports are generated using an in-house script

113 based on the Stanford json file output.

### 114 Assessment of assay performance

115 Validation criteria were pre-defined and based on WHO "Recommended methods for

validating an in-house genotyping assay for surveillance of HIV drug resistance" with minor

8

117	modifications (WHO, 2020). In brief, these criteria included that 100% of known mutations
118	must be detected and $\geq$ 90% of pairwise comparisons must be at least 98% identical. The
119	WHO guidance also recommended meeting sensitivity for amplification $\geq$ 95% of samples
120	with viral loads between 500 and 1000 cp/mL amplified and successfully genotyped ( $n \ge 10$ ).
121	This criteria had to be modified as the ViroSeq (our "gold-standard") is not suitable for viral
122	loads $<2000 \text{ cp/mL}$ to sensitivity for amplification $\ge 95\%$ of samples with viral loads $>2000$
123	cp/ml must be amplified and successfully genotyped (n $\ge 10$ ).
124	Performance metrics used to assess the new method were as follows: (1) accuracy; (2)
125	precision/reproducibility; (3) sensitivity.
126	Accuracy
127	Using sensitivity or specificity calculations in the context of sequencing comparisons are
128	impractical and misleading as there are no "real" true negatives especially when including
129	minor mutations in an RNA virus that has a low barrier for genomic change.
130	Therefore, the Jaccard similarity coefficient (J) was employed which gauges the diversity and
131	similarity of samples. The Jaccard coefficient measures similarity between finite sample sets,
132	and is defined as the size of the intersection divided by the size of the union of the sample
133	sets.
134	J(ViroSeq,WGS)=(  ViroSeq ∩WGS  )/(  ViroSeq∪WGS  )
135	By design values are between 0 and 1 with higher values indicating greater similarity.
136	The level of agreement between the new test and the reference test was assessed by
137	comparing consensus nucleotide sequences, amino acid sequences, subtype, major and minor
138	mutations detected. To compare nucleotide sequences, both WGS data and the Viroseq
139	FASTA files were mapped to HIV-1 reference HBX2 using clustalW (Chenna, 2003).

9

Relevant regions of the *Pol* region (1.3kbp) were extracted from the aligned files. Bases
common to both datasets including ambiguous assigned bases in Viroseq data were extracted
as well as mutations through pairwise comparisons.

### 143 Linearity, Limit of Detection and Limit of Quantification

Both the limit of detection (LoD) and limit of quantification (LoQ) were assessed using a

145 panel of standards comparing viral load to the number of reads mapping to the reference

- 146 (HIV-1- HBX2). Although, the veSEQ-HIV assay is capable of estimating viral load based
- 147 on reads mapping to the reference provided a panel of quantification standards is included in
- 148 each run (Bonsall, 2020), this was not formally assessed given the predicted number of
- samples in our setting.

### 150 **Precision/Reproducibility**

151 Inter- and intra-run agreement was assessed by running replicates on different runs and

152 within the same run. For intra-run comparison, a set of five samples were included on the

same run across three different runs; viral loads ranged between 3475 and 100,000 cp/mL and

included subtypes B, C and CRF01\_AE. For inter-run comparison, a set of eight samples

were included on two different runs; viral loads ranged between 3435 and 100, 000 cp/mL

and included subtypes B and CRF01\_AE. A summary of the replicates can be found in **Table** 

157 **2** below.

The WHO recommends (3 x 5 replicates) to determine inter-run precision, due to limited
remaining plasma from previously tested samples, inter-run precision was determined using a
(2 x 8 replicates) approach.

10

### 161 Specificity

162	Specificity was assessed by a negative control (PCR HIV negative plasma) included in all
163	runs. Subsequent routine clinical runs have included a phosphate-buffered saline negative
164	control. Possible interfering substances were not assessed as sequencing would only be
165	performed on confirmed HIV positive samples.

### 166 Quality control Criteria

- 167 A set of quality control (QC) criteria were established to assess both run and sample data
- 168 quality prior to analysis. We included sequencing run metrics as specified by the
- 169 manufacturer (Illumina) as well as criteria to review individual raw read data, inclusive of the
- 170 negative control. For review of individual sample data, we referred to guidelines established
- 171 by the Winnipeg Consensus for read quality control (QC), read alignment, reference
- 172 mapping, HIVDR interpretation and reporting (Ji, 2018).

### 173 Clinical Reporting

- 174 Development of our clinical reporting strategy involved discussion with treating clinicians in
- 175 our network and well as incorporating requirements set by our accreditation, WHO
- 176 recommendations and guidelines established by the Winnipeg Consensus (Ji, 2018; WHO,
- 177 2020).

### 178 **Results**

- 179 Accuracy
- 180 Accuracy of nucleotide sequences
- 181 The pairwise analysis of the *Pol* region resulted in an overall Jaccard coefficient of similarity
- 182 of 0.998, with 98,459 bases shared and 145 SNPs (single nucleotide polymorphisms)
- 183 differences between isolate pairs.

11

### 184 Accuracy of subtyping

Concordant subtypes were achieved for 98% (n=65/66) of patient samples. One sample was misidentified as subtype CRF\_14\_BG rather than subtype B. This sample had low viral load (2790 cp/ mL), resulting in less than 1000 mapped reads and suboptimal coverage across the PR gene. Provided samples obtained >1000 mapped reads 100% accuracy of subtyping could be obtained.

Accuracy of Major Drug Mutations. Due to the low prevalence and success of current 190 ART, a limited repertoire of major drug mutations could be sourced and included 5 different 191 PR, 19 NNRTI/NRTI and 5 IN major mutations. There were 19 discordant major drug 192 mutation calls between the two methods. All discordances were able to be resolved. The 193 194 majority (n=9) on the ViroSeq chromatogram were assigned as an ambiguous base with 195 reporting calling both wild-type and a DRM. These were all present on WGS but at a subconsensus level (defined when <50% but >5% of reads mapping to the alternative allele at a 196 197 >20 fold read depth). The remaining discordance were as a result of: (1) incorrect manual base assignments on ViroSeq (n=5); and (2) no coverage across region of interest on WGS 198 (n=5). No false positive DRMs were detected on WGS. Taking these additional results into 199 200 account, the overall accuracy/concordance for detection of major mutations was 100% with a Jaccard similarity coefficient of 1.0. A summary of these results can be found in Table 3. 201

202 Accuracy of Minor Drug Mutations

203 Only accuracy for PR and RT were examined. Three (3/601; 0.4%) and 29 (29/1249; 2%)

discordant minor PR and RT mutation calls were identified respectively while 1 (1/569;

205 0.2%) and 13 (13/2499; 1%) potential WGS false positives were identified. The majority of

the false positive (n=10) minor mutations occurred on the boundaries of the ViroSeq

207 amplicons resulting in higher uncertainty of basecalls. Irrespective, the overall

12

- accuracy/concordance for detection of Minor mutation was 98%. The overall Jaccard
- 209 coefficient of similarity was 0.975. A summary of concordance of minor drug mutations is
- 210 available in **Supplementary Table 4**.

### 211 Limit of Detection and Limit of Quantification

### 212 Mapped reads

Eight samples (8/82; 10%) run on WGS had suboptimal coverage (<1000 mapped reads).

- Five (5/8; 63%) of these samples had low viral loads (2000 5000 cp/mL). The depth of
- coverage affected all regions when <1000 mapped reads were obtained while >1000 mapped
- reads gave excellent coverage depth for all regions. Results are summarised in **Table 4**.

#### 217 By viral load

- A significant linear correlation (R=0.74; p<0.01) between viral load and number of mapped
- reads. (Figure 1A and 1B) was detected. Low viral loads (2000 5000 cp/mL) gave
- inconsistent results but were linked to the number of mapped reads with <1000 mapped reads
- in six of 13 isolates (46%). The remaining seven represented possible failed WGS runs.
- 222 These were unable to be repeated as no further sample was available. Furthermore, as all
- samples had been stored with an unknown number of freeze-thaw cycles, re-quantification
- 224 was not possible to exclude sample RNA degradation as the cause.

### 225 Linearity

- A significant linear relationship (R=0.99; p<0.001) was detected when including a
- 227 commercial standard AcroMetrix HIV-1 Panel (Thermo Fisher Scientific, Waltham,
- 228 Massachusetts, USA). With decreasing viral loads a reduction in: (1) the percentage coverage
- across genes; and (2) the number of mutations was detected. At low viral loads <2000 cp/mL
- 230 potential false positive (FP) mutations were detected (Supplementary Table 1). A limit of

13

. 1

231	detection for HIV-1 was determined to be 100 cp/mL. With respect to reporting the number
232	of mapped reads was the best correlate with optimal reporting requiring a minimum of 1000
233	mapped reads.

100

### 234 Inter-run (reproducibility) and intra-run (repeatability) of WGS method

- 235 The inter-run variability (good Jaccard similarity index) both across the whole genome
- 236 (J=0.993) as well as across the *Pol* gene (J=0.999) was within the expected performance with
- an average of 437 SNPs across the whole genome and 4 SNPs across the *Pol* gene between
- 238 runs.
- 239 Similarly, the intra-run variability (good Jaccard similarity index) was adequate both across
- the whole genome (J=0.972) as well as across the *Pol* gene (J=0.999) with an average of 130
- 241 SNPs across the whole genome and 4 SNPs across the *Pol* gene between runs. These results
- are summarised in **Table 2**.

### 243 Specificity

- 244 No evidence of contamination across all validation runs or subsequent clinical runs was
- detected with an average of 20 (range 0-548) reads for the negative control. Although reads
- 246 represented HIV reads in a small subset, all negative control assemblies failed and mapping
- to the reference (HIV-1- HXB-2) was unsuccessful with 0% coverage and 0% depth across

248 the three regions (PR, RT, IN) of the HIV genome.

- 249 Quality Control Criteria
- QC metrics and their corresponding limits/criteria for sequencing runs are presented in
  Supplementary Table 2.

#### 14

### 252 Clinical reporting

In the transition to NGS-based methods, WHO has recommended presenting resistance 253 254 results in the same way as previous SS-based methods (WHO, 2020). Thus, reports include the same data output generated by the ViroSeq assay- subtype identification and lists 255 identified DRMs mutations and their associated susceptibility interpretations. 256 With interest expressed from the treating clinicians in our network, the presence of sub-257 consensus variants containing major drug resistance mutations are also included (reporting 258 when frequency greater than 5% and with appropriate caveats) (Ji, 2018). These findings are 259 presented in an iterative way with additional mutation score and interpretation change 260 reported alongside consensus interpretations. With the clinical relevance of sub-consensus 261 262 variants of <20% frequency still under debate, this leaves the choice to consider any changes 263 in interpretation to the treating clinician. An example report can be found in **Supplementary** file 1. 264

#### 265 Discussion

In this study, we provide our in-house validation of the veSEQ-HIV assay in its utility for
HIVDR in an Australian clinical microbiology laboratory. The veSEQ-HIV assay with minor
modifications, met our pre-specified validation criteria based on the WHO "Recommended
methods for validating an in-house genotyping assay for surveillance of HIV drug resistance"
(WHO, 2020). We therefore deemed the assay fit for purpose and able to replace the ViroSeq
assay in our laboratory.

We achieved a Jaccard similarity coefficient (J) of 0.998 for pairwise nucleotide comparisons of the *Pol* gene and detected 100% of major mutations (Criteria 1: Accuracy 100% of known mutations must be detected).

15

A limitation of our validation includes the small number of mutations encountered. We only 275 encountered (11/56; 19%) NRTI; (8/49; 16%) NNRTI, 5/57; 9% PR and 3/43; 7% IN DRMs 276 (All DRMs encountered are listed in Supplementary Table 3). Ideally, our validation set 277 would have included all known mutations that affect clinical interpretation i.e. all known 278 DRMs, however, practically, this is infeasible as hundreds of mutations would need to be 279 covered (WHO, 2020). We attempted to cover as many mutations as possible but were 280 281 limited to samples that had previously been referred to our laboratory for testing that had sufficient remaining plasma. Ongoing clinical testing should add to the DRMs encountered. 282 283 Pairwise comparison exhibited low inter-and intra-run variability across the whole genome (J=0.993; J=0.972 respectively). Agreement was highest when limited only to the Pol gene 284 (both J=0.999). (Criteria 2:  $\geq$ 90% of pairwise comparisons must be at least 98% identical). 285 This supports previous finding of relative conservation across the *Pol* gene relative to the rest 286 of the genome (Troyano-Hernáez, 2022). 287 We identified 100% of subtypes correctly (Criteria 3: Sensitivity for amplification:  $\geq$ 95% of 288 samples with viral loads >2000 cp/mL must be amplified and successfully genotyped (n 289 ≥10)). 290 There were 4 subtypes (B, C, CRF01 AE and CRF02 AG) represented in our sample set. 291 The majority of samples were subtype B (n=48/66; 72%) followed by subtype CRF01 AE 292 293 (n=20/66; 18%). This is in keeping with previous Australian epidemiological data identifying subtype B as the most prevalent and CRF01 AE as one of the dominant non-B subtypes of 294 increasing prevalence (Castley, 2017). This indicates that while we could not equally 295 296 represent all HIV genotypes due to lack of sample availability the subtypes in our sample are representative of circulating HIV in Australia. Irrespective, we do not expect there to be any 297 negative bias in "uncommon" genotypes as veSEQ-HIV probes have been designed and 298

16

299 previously shown to consistently recover genomes from these "uncommon" subtypes

including C, A (A1 &A2), D, G and J (Bonsall, 2020).

301 The veSEQ-HIV assay is now in routine use in our laboratory and has been used to

302 successfully sequence and generate over 100 HIVDR and genotyping reports to clinicians

303 across the state of New South Wales, Australia.

Running limited batches (eight patient samples) has allowed easy implementation of the assay into the workflow of our small sequencing laboratory with minimal staff and equipment and has been an ideal use of a small desktop sequencer such as the Illumina iSeq100. Despite small batches, reagent cost per assay is still significantly reduced compared to the previous commercial assay (from \$360 to \$200). Assay batching flexibility also allows for future throughput increases utilising automated liquid-handing for library preparation and larger sequencing platforms (e.g. Illumina MiSeq).

311 Processing of NGS data has been identified as a major hurdle in implementation of NGS-

based HIVDR. The Winnipeg Consensus has established preliminary guidelines for read

quality control (QC), read alignment and reference mapping, variant calling and QC, HIVDR

interpretation and reporting as well as general analysis of data management (Ji, 2018). These
guidelines were invaluable in developing our bioinformatics, QC and clinical reporting
strategy.

Further hurdles for NGS-based HIVDR include lack of specifically developed external

quality assessment (EQA) strategies and programs (Lee, 2020; Ji, 2018) as current HIVDR

319 EQA are still designed for SS-based methods. In the transition to NGS-based methods, WHO

320 has recommended configuring NGS methods to present results in the same way as SS-based

methods (WHO, 2020). Thus, while not ideal, NGS-based HIVDR can still be used to

322 produce results formatted as SS-based HIVDR outputs, permitting participation in current

323 EQA programs such as the HIVDR programs from Quality Control for Molecular

- 324 Diagnostics (QCMD) that our laboratory participates in.
- 325 Informal sample exchange between laboratories offers an alternative transitional EQA
- 326 strategy to meet accreditation needs, however, very few laboratories are currently performing
- 327 NGS-based HIVDR in Australia. We look forward to more laboratories taking up NGS-based
- 328 methods to make this another transitional EQA option.
- 329 Despite this, there remains an urgent need for appropriate EQA programs and materials to be
- made available as these approaches overlook the abundance and available complexity in NGS
- HIVDR data, particularly its ability to detect sub-consensus variants at low levels (Lee,
- 332 2020).
- 333 In addition, appropriate reference materials for validation of sub-consensus variant detection
- do not yet exist. Our reporting strategy for sub-consensus variants followed the
- recommendations from the Winipeg consensus with a 5% frequency threshold suggested to
- account for errors/bias introduced during assay steps such as reverse-transcription, PCR,
- sequencing steps etc. (Ji, 2018; Casadellà, 2017). While we did not quantify the sensitivity of
- variant detection in this validation, this threshold is likely conservative with estimates of
- 339 minority variant frequency likely to be more robust using the probe-based veSEQ-HIV
- 340 method as biases introduced by PCR are minimised and contamination is computationally
- 341 controlled (Bonsall, 2020). Our reporting includes necessary caveats to sub-consensus variant
- reporting and leaves the choice act on subsequent drug susceptibility interpretation changes tothe treating clinician.
- Well-characterised sample panels including both clinical and synthetically constructed
  samples containing sub-consensus variants are needed to assess each laboratory's ability to
  detect sub-consensus variants accurately (Lee, 2020).

18

## 347 Conclusion

348	The veSEQ-HIV assay provides a robust and cost-effective NGS method for HIVDR in a
349	diagnostic setting. veSEQ-HIV demonstrated satisfactory and consistent performance
350	including low inter-and intra-run variability and good accuracy in detection of DRMs in
351	samples with >1000 mapped reads (achievable in samples with VL >1000 cp/mL) when
352	compared to the "gold-standard" SS-based ViroSeq assay. The veSEQ-HIV assay met all our
353	pre-set criteria based on the WHO "Recommended methods for validating an in-house
354	genotyping assay for surveillance of HIV drug resistance" and has successfully replaced the
355	previous SS-based ViroSeq assay in our laboratory.
356	The assay meets current needs for clinical reporting (as SS-like results) to meet requirements
357	of our diagnostic laboratory accreditation and to participate in current EQA programs as well
358	as the ability to report on the presence of sub-consensus variants with appropriate caveats. As
359	HIVDR transitions from SS-based methods to NGS and the clinical relevance of sub-
360	consensus variants is further clarified, the veSEQ-HIV meets both current and future needs
361	for HIVDR testing in a diagnostic setting.
362	Funding
363	None
364	Declaration of Competing Interest
365	All authors have completed the ICMJE uniform disclosure form at
366	www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the

- 367 submitted work; FJL is on the Gilead Sciences Advisory board and has received consulting
- 368 fees and payments for educational events.
- 369

#### 370 Acknowledgements

- 371 Thanks to Alicia Beukers for her preliminary work in this validation. Thanks also go to the
- 372 Clinical Immunology Laboratory at RPAH for providing the study samples and sharing the
- 373 ViroSeq comparison data. Thanks to the Oxford group for providing the custom probe
- 374 sequences to allow us to perform the veSEQ-HIV in our laboratory.

#### 375 Contributions

- 376 FJ drafted the manuscript.
- 377 FJ, TL, RF performed the validation testing
- 378 SVH, AP, FJL designed the validation
- 379 SVH developed the in-house pipeline, performed the bioinformatics and statistical analysis
- 380 MAA developed the custom probe sequences
- 381 TG assisted with pipeline development
- 382 DB, RB shared protocols and assisted with assay implementation
- 383 DB, RB, SVH, AP, FJL reviewed the manuscript
- 384 Appendix. Supplementary materials
- 385 Supplementary file 1: Example Clinical Report
- 386 Supplementary file 2: Probe sequences
- 387 Supplementary file 3: Supplementary data

388

20

### 389 **References**

- Bonsall, D. G.-C.-D.-M. (2020). A Comprehensive Genomics Solution for HIV Surveillance
  and Clinical Monitoring in Low-Income Settings. *Journal of Clinical Microbiology*,
  58(10). doi:https://doi.org/10.1128/JCM.00382-20
- 393 Casadellà, M. &. (2017). Deep sequencing for HIV-1 clinical management. Virus research,

394 *239*, 69–81. doi:https://doi.org/10.1016/j.virusres.2016.10.019

- 395 Castley, A. S. (2017, May 10). Australian Molecular Epidemiology Network-HIV (AMEN-
- HIV). A national study of the molecular epidemiology of HIV-1 in Australia 2005-

2012. *PLoS One*, *12*(5), e0170601. doi:doi: 10.1371/journal.pone.0170601

398 Chenna, R. S. (2003). Multiple sequence alignment with the Clustal series of programs.

399 *Nucleic acids research*, *31*(13), 3497–3500. doi:https://doi.org/10.1093/nar/gkg500

- Chris Wymant, F. B. (2018). Easy and accurate reconstruction of whole HIV genomes from
  short-read sequence data with shiver. *Virus Evolution*, 4(1), vey007.
- 402 Fogel, J. M. (2020). Performance of a high-throughput next-generation sequencing method
- 403 for analysis of HIV drug resistance and viral load. *The Journal of antimicrobial*

404 *chemotherapy*, 75(12), 3510–3516. doi:https://doi.org/10.1093/jac/dkaa352

- Guy, R. J. (2007). HIV diagnoses in Australia: diverging epidemics within a low-prevalence
  country. *The Medical journal of Australia, 187*(8), 437–440.
- 407 doi:https://doi.org/10.5694/j.1326-5377.2007.tb01353.x
- 408 Ji, H. E.-R.-J. (2018). Bioinformatic data processing pipelines in support of next-generation
- 409 sequencing-based HIV drug resistance testing: the Winnipeg Consensus. *Journal of*

410 *the International AIDS Society, 21*(10), e25193.

411 doi:https://doi.org/10.1002/jia2.25193

412	Kirby Institute. (2018). HIV, viral hepatitis and sexually transmissible infections in Australia:
413	annual surveillance report 2018. Kirby Institute. Sydney: UNSW Sydney. Retrieved
414	from https://kirby.unsw.edu.au/report/asr2018
415	Lee, E. R. (2020). External Quality Assessment for Next-Generation Sequencing-Based HIV
416	Drug Resistance Testing: Unique Requirements and Challenges. Viruses, 12(5), 550.
417	doi:https://doi.org/10.3390/v12050550
418	Liu TF, S. R. (2006, April 28). Web Resources for HIV type 1 Genotypic-Resistance Test
419	Interpretation. Clin Infect Dis, 42(11), 1608-18.
420	Metzner, K. J. (2009). Minority quasispecies of drug-resistant HIV-1 that lead to early
421	therapy failure in treatment-naive and -adherent patients. Clinical infectious diseases :
422	an official publication of the Infectious Diseases Society of America, 48(2), 239–247.
423	doi:https://doi.org/10.1086/595703
424	Rhee, S. Y. (2003). Human immunodeficiency virus reverse transcriptase and protease
425	sequence database. Nucleic Acids Research, 31(1), 298-303.
426	doi:https://doi.org/10.1093/nar/gkg100
427	Shafer, R. W. (2006). Rationale and Uses of a Public HIV Drug-Resistance Database.
428	Journal of Infectious Diseases, 194(Suppl 1), S51-8.
429	Simen, B. B. (2009). Low-abundance drug-resistant viral variants in chronically HIV-
430	infected, antiretroviral treatment-naive patients significantly impact treatment
431	outcomes. The Journal of infectious diseases, 199(5), 693-701.
432	doi:https://doi.org/10.1086/596736

22

- 433 Taylor, T. L. (2019). A MiSeq-HyDRA platform for enhanced HIV drug resistance
- 434 genotyping and surveillance. *Scientific reports*, *9*(1), 8970.
- 435 doi:https://doi.org/10.1038/s41598-019-45328-3
- 436 Troyano-Hernáez, P. R. (2022). Genetic Diversity and Low Therapeutic Impact of Variant-
- 437 Specific Markers in HIV-1 Pol Proteins. *Frontiers in microbiology*, *13*, 866705.
- 438 doi:https://doi.org/10.3389/fmicb.2022.866705
- 439 WHO. (2020). WHO HIVResNet HIV DRUG RESISTANCE; LABORATORY OPERATIONAL
- 440 FRAMEWORK; ANNEX 3. Recommended methods for validating an in-house
- 441 *genotyping assay for surveillance of HIV drug resistance.* World Health Organization.
- 442 Retrieved from https://www.jstor.org/stable/pdf/resrep27859.13.pdf
- Wood DE, L. J. (2019). Improved metagenomic analysis with Kraken 2. *Genome Biology*,
  20(1), 257.
- 445 Wymant, C. B.-B. (2018). Easy and accurate reconstruction of whole HIV genomes from
- short-read sequence data with shiver. *Virus evolution, 4*(1), vey007.
- 447 doi:https://doi.org/10.1093/ve/vey007

448

### **1** Table 1. Isolate baseline characteristics

Subtype	Number of	Mean viral load	Viral load range	Number Surveillance Drug Resistance Mutations			
	samples	(cp/mL)		PR**	<b>B</b> T**	IN	
В	48	364275	2260-2914185	6	54	5*	
С	3	41444	14309-81222	0	5	0*	
CRF01_AE	13	167506	1700-847000	0	26	0*	
CRF02_AG	2	53025	1050- 105000	0	4	0*	

2 \* Only 5/66 (8%) samples had integrase testing at baseline. Integrase is not included in ViroSeq assay.

3 \*\* Surveillance Drug Resistance Mutations as determined by ViroSeq assay.

	Number of	Replicates per	Viral load	Subtypes	Jaccard Similarity-	Jaccard Similarity-
	samples	sample	(cp/mL)		whole genome (mean	Pol gene (mean SNPs)
					SNPs)	
Intra-run	5	3	3435 - 100,000	В, С,	0.972 (130)	0.999 (4)
				CRF01_AE		
Inter-run	8	2	3435 - 100,000	B, CRF01_AE	0.993 (437)	0.999 (4)

4 Table 2. Intra- and inter-run comparison including Jaccard Similarity and SNP numbers across whole-genome and across *Pol* region

# 5 Table 3. Concordance of major drug mutations between methods

Major mutation	Concordant	Discordant	Presence of	ViroSeq poor	WGS poor	Discordance	Overall accuracy
location	mutation calls	mutation calls	sub-population	coverage/false calls	coverage	resolved (%)	
PR	6	3	1	2	-	100	100%
						(n=3/3)	(n=6/6)
RT	84	16	8	3	5	100	100
						(n=16/16)	(n=84/84)
IN	5*	-	-	-	-	-	100
							(n=5/5)
Total	-	-	9	5	5	100	100
						(n=19/19)	(n=95/95)

6 Please note: Replicates were included in mutation analysis

7 \* SS IN results only available for 5/66 samples

# 8 Table 4. WGS QC metrics based on number of mapped reads

No. mapped Reads	No. of samples	Average Depth Coverage				
		PR region	RT region	IN region		
<1000	8	71% @ 9 fold	42% @ 8 fold	52% @ 7 fold		
>1000	78	99% @ 2914 fold	99% @ 3465 fold	99% @ 3372 fold		





Figure 1A& 1B. Scatterplot of viral load and number of mapped reads for sequenced isolates (1A) and correlation and prediction curve (1B).